Credits: Canva
When the sun is out after a long winter, every one loves it. But not the people of Canary Islands. Tourists there are being warned about the "unusually high risk" of UV rays this week. The Ministry of Health for this holiday destination has urged both, residents and visitors to take extra precautions and preventative measures to limit the impact of sun exposure over their body and skin.
The Ministry observed Aemet, Spain's national weather agency for the forecast which showed higher than normal UV or ultraviolet radiation levels in the region. It is in this backdrop that everyone in the region are requested to be extra careful when they are out in the sun. UV levels are set to reach 7, which is a 'high risk' in La Palma, El Hierro, La Gomera and Gran Canaria. Other regions like Tenerife, Fuerteventura and Lanzarote are expected to reach a level 6, which is also classed as 'high risk'.
As per the World Health Organization (WHO), a UV index is a measure of the level of UV radiation, which ranges from zero upward. The higher the UVI, the greater potential for damage to skin and eye and the less time it takes for harm to occur, notes WHO.
The range 1 to 2 represents a low risk, 2 to 5 is moderate, 6 to 7 is at high risk, 8 to 10 is at very high and anything over 11 is extremely risky for anyone to stay out.
UV radiation levels fluctuate throughout the day, with the highest values occurring during the four-hour period around solar noon. The reported UV Index (UVI) typically reflects this daily peak. Depending on geographic location and the use of daylight saving time, solar noon falls between 12 p.m. and 2 p.m. In some countries, sun protection advisories are issued when UV levels are expected to reach 3 or higher, as exposure at these levels increases the risk of skin damage, making protective measures essential.
While sun bathing is good, being out in the sun when the UVI indicates a high or very high risk, may cause you health concerns. It can lead to sunburn, premature skin aging, incresed risk of skin cancer, eye damage and in severe cases, heat related disease.
It is one of the most common skin injury which happens when there is excess exposure to UV radiation from the sun. This happens when the UV radiation directly damages the DNA skin cells. These damaged cells die and shed, this is why people experience peeling after getting a sunburn.
This is also a common occurrence when your body loses too many fluids or electrolytes. It can also interfere with your normal body functions. You may feel dehydrated, especially when you are out in the sun, but not well hydrated. The most common symptoms are dizziness, fatigue and headache on hot days.
This is an electrolyte disorder in which your body experiences low sodium in blood. The symptoms could lead to nausea, confusion and even weakness. There are extreme cases when one may have seizures, slip into coma or die.
This is one of the most common consequence of being out under the hot sun. Dehydration with prolonged heat exposure can lead to heat exhaustion.
When you are out under the sun and your body's core temperature cross 104°, heatstroke may occur. This is also known as sunstroke. As per the Centers for Disease Control and Prevention (CDC), it causes more than 600 deaths each year in the United States.
Credit: Times Network Health Summit 2026
The experts stressed the urgent need to tackle India's growing obesity crisis—particularly among children.
Speaking during a panel discussion on the future of women's and child healthcare, Dr. Sivaranjani Santosh, often referred to as the "ORS Lady of India," praised India's public health achievements, including the successful Pulse Polio Program, malaria control efforts, and improvements in child nutrition.
However, she cautioned that new challenges now threaten the country's health gains.
"There were many things we are lagging a bit also," Dr. Santosh said, stressing the need for fair food labelling, responsible marketing, and stricter regulation of irrational drug combinations.
She issued a stark warning about unhealthy eating habits, saying, "This junk food pandemic, this is where India needs to really, really focus on. Childhood obesity is a pandemic now. And it's like do or die right now for us."
Her comments highlighted growing concerns that poor nutrition and processed foods are driving obesity among children, increasing their risk of chronic illnesses later in life.
Echoing the concerns, Dr. T. Rajeshwari Reddy, Senior Consultant Obstetrician, Gynecologist, and Laparoscopic and Robotic Surgeon at Continental Hospital, explained that unhealthy lifestyles beginning in childhood are now contributing to a rise in hormonal disorders, infertility, and high-risk pregnancies.
"We are seeing a lot of people with hormonal imbalances and a lot of issues from teens, and that is what gets translated into infertility and high-risk pregnancy," she said.
Dr. Rajeshwari stressed that prevention must begin early. "The beginning has to be from birth only," she said, urging families to prioritize home-cooked meals, healthy routines, adequate sleep, and reduced screen time. She added that preventive healthcare should become the foundation of India's health strategy over the next decade.
Experts agreed that the future of Indian healthcare will depend on preventive medicine, technology, artificial intelligence, and stronger public-private partnerships to improve access to healthcare, particularly in rural areas.
They urged that India's fight against childhood obesity and lifestyle-related diseases must begin at home, with healthier food choices, greater awareness, and prevention from an early age.
Meanwhile, the AI in healthcare panel featured Prof. Renu John, IIT Hyderabad; Nishan Ali, Founder & CEO, Neurologic AI; Dr. Rahul Sawakhande, CEO, Aakaar Medical Technologies; and Dr. Rajah V. Koppala, Vascular & Interventional Radiologist and Founder, AVIS Vascular Center. The experts discussed how AI is driving predictive, data-led healthcare by improving diagnostics, telemedicine, and early disease detection while complementing doctors. They also stressed the need for better regulations, India-specific datasets, stronger data privacy, and greater collaboration between clinicians and engineers to expand quality healthcare across India.
The Times Now India Health Summit 2026 – South Edition commenced in Hyderabad, bringing together leading voices from government, medicine, research, and the healthcare industry to discuss the future of India's healthcare system. The summit featured renowned doctors, policymakers, hospital leaders, researchers, and healthcare innovators, with discussions spanning preventive healthcare, artificial intelligence, women's health, public health policy, and medical innovation.
Credit: iStock
The Ebola outbreak caused by the Bundibugyo virus has reached 915 confirmed cases and 210 deaths in the Democratic Republic of the Congo (DRC) and Uganda, according to the Africa Centers for Disease Control and Prevention (Africa CDC).
The situation remains serious, with ongoing transmission reported in eastern DRC. Ituri Province continues to be the epicentre of the outbreak, accounting for the majority of confirmed cases in the country. The most affected health zones include Bunia, Mongbwalu, and Rwampara.
North Kivu has reported fewer cases than Ituri but has recorded a higher case-fatality rate, particularly in Katwa and Beni. Health officials say this underscores the need for early detection, safe referrals, quality clinical care, and strengthened infection prevention and control measures.
In Uganda, 19 confirmed cases and two deaths have been reported to date. No new cases have been recorded since June 5, 2026.
Africa CDC has identified several challenges hampering response efforts, including gaps in
"Communities are central to stopping this outbreak. The response will only succeed if people trust the information they receive, know where to seek care, and feel that response teams are working with them," Africa CDC said in a statement.
Also read: US FDA Panel Recommends First-Ever mRNA Flu Shot For Older Adults: All About The Moderna Vaccine
Meanwhile, the World Health Organization (WHO) had warned that the outbreak is spreading rapidly, even as response measures are being intensified.
"The outbreak remains serious and is evolving very fast. However, I have seen a response that is growing stronger every day," said Marie-Roseline Belizaire, WHO Regional Emergencies Director for Africa, speaking to reporters in Bunia, the epicentre of the outbreak.
The WHO estimates that at least 95 per cent of contacts must be traced to effectively contain the outbreak. As per Belizaire, contact tracing has improved to 75 per cent.
Africa CDC epidemiologist Dr. Wessam Mankoula said the outbreak is approximately three times larger than any previous Ebola outbreak at a similar stage, four weeks after a public health emergency declaration, AP News reported.
Although the outbreak was officially declared on May 15, health officials believe the virus had been circulating undetected for some time beforehand, contributing to its wider spread.
Another major concern is that the outbreak is being driven by the Bundibugyo strain of Ebola virus, for which there are currently no approved antiviral treatments.
Community mistrust of healthcare workers and public health officials, along with reliance on traditional beliefs and healers, is also complicating containment efforts.
Credit: iStock
The US Food and Drug Administration's independent advisory panel has recommended approval of Moderna's mRNA-based influenza vaccine for older adults.
The panel backed the vaccine, known as mFLUSIVA, for adults aged 50 years and older, concluding that its benefits outweigh its risks.
If ultimately approved by the FDA, mFLUSIVA would become the world's first messenger RNA (mRNA) vaccine for seasonal influenza. The development could provide a new tool against a disease that causes an estimated 15 million to 60 million illnesses, 180,000 to 700,000 hospitalizations, and 17,000 to 75,000 deaths annually in the United States, according to data from the US Centers for Disease Control and Prevention (CDC).
The recommendation came from the Vaccines and Related Biological Products Advisory Committee (VRBPAC), which reviews vaccine applications and advises the FDA.
The meeting marked the committee's first review of a new vaccine application since 2023 and could lead to the first vaccine approval under the second Trump administration.
In a unanimous vote, all nine panel members supported the use of Moderna's mFLUSIVA vaccine for adults aged 50 to 64 years, as well as for those aged 65 years and older—the age group that had previously raised regulatory concerns.
Also read: No Women Aged 20-24 Died of Cervical Cancer in England Over Five Years, Thanks to HPV Vaccine
However, before the vaccine can be made available for the upcoming flu season, it must receive formal FDA approval and be recommended by the CDC's Advisory Committee on Immunization Practices (ACIP). The CDC advisory panel has not recently convened due to ongoing legal and administrative challenges. An FDA decision on the vaccine is expected by August 5.
According to Moderna, the vaccine outperformed standard-dose flu vaccines in adults aged 50 to 64 years.
In a large clinical trial involving approximately 40,000 adults aged 50 years and older, Moderna's mRNA vaccine reduced influenza cases by about 27% compared with another routinely used flu vaccine.
The company also conducted a smaller study among adults aged 65 years and older. The results showed that mFLUSIVA generated a strong immune response compared with a high-dose influenza vaccine already recommended for seniors.
FDA adviser Dr. Anna Durbin of Johns Hopkins University described the immune-response data as "very compelling," adding that "the vaccine looks very promising," AP News reported.
Read More: Sickle Cell Disease: Why India Must Add Curative Treatment to Meet Its 2047 Elimination Goal
Like Moderna's COVID-19 vaccines, mFLUSIVA uses messenger RNA technology. Rather than introducing a weakened or inactivated virus, mRNA vaccines deliver genetic instructions that help the body's cells produce proteins that trigger an immune response. This approach allows vaccines to be updated more quickly and may improve protection against evolving viruses.
Moderna's data showed no major safety concerns.
The most commonly reported side effects included:
These reactions were generally temporary and are commonly seen with many vaccines. However, they occurred somewhat more frequently than with currently available flu vaccines. FDA reviewers noted that this is typical of mRNA-based vaccines.
If approved, Moderna plans to conduct a large post-approval study involving approximately 400,000 adults aged 65 years and older.
Half of the participants will receive the mRNA vaccine, while the other half will receive one of the currently recommended flu vaccines for seniors. The study is expected to continue across two influenza seasons.
A Moderna executive said the company hopes to make the vaccine available to patients in time for the upcoming flu season, Reuters reported.
© 2024 Bennett, Coleman & Company Limited